Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-01-30

Clinical Trial Update: E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing E7389 to physician's choice in locally recurrent or metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • E7389 (eribulin)

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-01-30